(Q41188377)

28 September 2017

1 reference

title

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer (English)

1 reference

28 September 2017

1 reference

1 reference

2

A Markham

0 references

author name string

L R Wiseman

series ordinal

1

1 reference

PubMed ID

8891470

28 September 2017

A Markham

series ordinal

2

1 reference

28 September 2017

1 October 1996

1 reference

28 September 2017

1 reference

28 September 2017

52

1 reference

28 September 2017

606-623

1 reference

28 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652040-00013

28 September 2017

0 references

cites work

Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.

1 reference

12 December 2020

In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials

1 reference

12 December 2020

Phase I clinical study of CPT-11. Research group of CPT-11

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study

1 reference

12 December 2020

[A model for sensitivity determination of anticancer agents against chemical-induced colon cancer in rats]

1 reference

12 December 2020

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

1 reference

12 December 2020

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

1 reference

12 December 2020

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

1 reference

12 December 2020

Current chemotherapeutic possibilities in the treatment of colorectal cancer

1 reference

12 December 2020

Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody

1 reference

12 December 2020

Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

12 December 2020

Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

1 reference

12 December 2020

Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy

1 reference

12 December 2020

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

12 December 2020

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

12 December 2020

Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the Germa

1 reference

12 December 2020

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

1 reference

12 December 2020

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

12 December 2020

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

12 December 2020

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

12 December 2020

Chemotherapy for colorectal cancer

1 reference

12 December 2020

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

1 reference

12 December 2020

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

The chemotherapy of colon cancer

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors

1 reference

12 December 2020

Eukaryotic DNA topoisomerases I.

1 reference

12 December 2020

[Antitumor effect of SN-38, active form of CPT-11, on human colorectal cancer cell line]

1 reference

12 December 2020

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer

1 reference

12 December 2020

Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients

1 reference

12 December 2020

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells

1 reference

12 December 2020

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients

1 reference

12 December 2020

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

Colorectal carcinoma: current problems and future perspectives

1 reference

12 December 2020

Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma

1 reference

12 December 2020

10.2165/00003495-199652040-00013

Identifiers

DOI

1 reference

PubMed ID

8891470

Dimensions Publication ID

28 September 2017

0 references

1 reference

PubMed ID

8891470